FATE

SEC source: 0001209191-22-003174 · doc4.xml · nonDerivative · entry 2

Wolchko J Scott · CIK 0001586893 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 431,546

F1 · kind: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 16,500 shares of Common Stock underlying RSUs granted to the reporting person on January 8, 2020 and 10,807 shares of Common Stock underlying RSUs granted to the reporting person on January 20, 2021. These sales were made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through "sell to cover" transactions and do not represent discretionary trades by the reporting person.

F3 · price: Represents the weighted average sale price of the shares sold ranging from $48.70 to $49.40 per share.

SEC source: 0001209191-22-003174 · doc4.xml · nonDerivative · entry 1

Wolchko J Scott · CIK 0001586893 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 436,065

F1 · kind: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 16,500 shares of Common Stock underlying RSUs granted to the reporting person on January 8, 2020 and 10,807 shares of Common Stock underlying RSUs granted to the reporting person on January 20, 2021. These sales were made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through "sell to cover" transactions and do not represent discretionary trades by the reporting person.

F2 · price: Represents the weighted average sale price of the shares sold ranging from $47.70 to $48.69 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 2 through 3.

SEC source: 0001209191-22-003172 · doc4.xml · nonDerivative · entry 2

TAHL CINDY · CIK 0001655472 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 155,849

F1 · kind: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 6,250 shares of Common Stock underlying RSUs granted to the reporting person on January 8, 2020 and 4,503 shares of Common Stock underlying RSUs granted to the reporting person on January 20, 2021. These sales were made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through "sell to cover" transactions and do not represent discretionary trades by the reporting person.

F3 · price: Represents the weighted average sale price of the shares sold ranging from $48.74 to $49.40 per share.

SEC source: 0001209191-22-003172 · doc4.xml · nonDerivative · entry 1

TAHL CINDY · CIK 0001655472 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 156,385

F1 · kind: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 6,250 shares of Common Stock underlying RSUs granted to the reporting person on January 8, 2020 and 4,503 shares of Common Stock underlying RSUs granted to the reporting person on January 20, 2021. These sales were made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through "sell to cover" transactions and do not represent discretionary trades by the reporting person.

F2 · price: Represents the weighted average sale price of the shares sold ranging from $47.72 to $48.71 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 2 through 3.

SEC source: 0001209191-22-003170 · doc4.xml · nonDerivative · entry 2

Valamehr Bahram · CIK 0001748177 · Chief R&D Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 146,532

F1 · kind: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 6,250 shares of Common Stock underlying RSUs granted to the reporting person on January 8, 2020 and 4,503 shares of Common Stock underlying RSUs granted to the reporting person on January 20, 2021. These sales were made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through "sell to cover" transactions and do not represent discretionary trades by the reporting person.

F3 · price: Represents the weighted average sale price of the shares sold ranging from $48.83 to $49.25 per share.

SEC source: 0001209191-22-003170 · doc4.xml · nonDerivative · entry 1

Valamehr Bahram · CIK 0001748177 · Chief R&D Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 146,950

F1 · kind: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 6,250 shares of Common Stock underlying RSUs granted to the reporting person on January 8, 2020 and 4,503 shares of Common Stock underlying RSUs granted to the reporting person on January 20, 2021. These sales were made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through "sell to cover" transactions and do not represent discretionary trades by the reporting person.

F2 · price: Represents the weighted average sale price of the shares sold ranging from $47.76 to $48.70 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 2 through 3.

SEC source: 0001209191-22-003168 · doc4.xml · nonDerivative · entry 2

Dulac Edward J III · CIK 0001821530 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,634

F1 · kind: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 4,503 shares of Common Stock underlying RSUs granted to the reporting person on January 20, 2021. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F3 · price: Represents the weighted average sale price of the shares sold ranging from $48.83 to $49.31 per share.

SEC source: 0001209191-22-003168 · doc4.xml · nonDerivative · entry 1

Dulac Edward J III · CIK 0001821530 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,024

F1 · kind: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 4,503 shares of Common Stock underlying RSUs granted to the reporting person on January 20, 2021. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: Represents the weighted average sale price of the shares sold ranging from $47.71 to $48.59 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 2 through 3.

SEC source: 0001209191-22-003054 · doc4.xml · nonDerivative · entry 3

Wolchko J Scott · CIK 0001586893 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 446,112

F1 · kind: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 62,500 shares of Common Stock underlying RSUs granted to the reporting person on January 7, 2019. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0001209191-22-003054 · doc4.xml · nonDerivative · entry 2

Wolchko J Scott · CIK 0001586893 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 446,213

F1 · kind: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 62,500 shares of Common Stock underlying RSUs granted to the reporting person on January 7, 2019. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F3 · price: Represents the weighted average sale price of the shares sold ranging from $46.72 to $47.67 per share.

SEC source: 0001209191-22-003054 · doc4.xml · nonDerivative · entry 1

Wolchko J Scott · CIK 0001586893 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 467,107

F1 · kind: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 62,500 shares of Common Stock underlying RSUs granted to the reporting person on January 7, 2019. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: Represents the weighted average sale price of the shares sold ranging from $45.72 to $46.70 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 2 through 3.

SEC source: 0001209191-22-003051 · doc4.xml · nonDerivative · entry 2

TAHL CINDY · CIK 0001655472 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 161,268

F1 · kind: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 15,000 shares of Common Stock underlying RSUs granted to the reporting person on January 7, 2019. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F3 · price: Represents the weighted average sale price of the shares sold ranging from $46.97 to $47.42 per share.

SEC source: 0001209191-22-003051 · doc4.xml · nonDerivative · entry 1

TAHL CINDY · CIK 0001655472 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 161,911

F1 · kind: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 15,000 shares of Common Stock underlying RSUs granted to the reporting person on January 7, 2019. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: Represents the weighted average sale price of the shares sold ranging from $45.71 to $46.65 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 2 through 3.

SEC source: 0001209191-22-003047 · doc4.xml · nonDerivative · entry 2

Valamehr Bahram · CIK 0001748177 · Chief R&D Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 151,102

F1 · kind: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 15,000 shares of Common Stock underlying RSUs granted to the reporting person on January 7, 2019. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F3 · price: Represents the weighted average sale price of the shares sold ranging from $46.77 to $47.42 per share.

SEC source: 0001209191-22-003047 · doc4.xml · nonDerivative · entry 1

Valamehr Bahram · CIK 0001748177 · Chief R&D Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 151,453

F1 · kind: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 15,000 shares of Common Stock underlying RSUs granted to the reporting person on January 7, 2019. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: Represents the weighted average sale price of the shares sold ranging from $45.71 to $46.65 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 2 through 3.

SEC source: 0001209191-22-000647 · doc4.xml · derivative · entry 6

TAHL CINDY · CIK 0001655472 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,643

Underlying: Common Stock · 50,000 shares

Expires 2028-01-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 8, 2021.

F6 · derivative.exercise_date: This option is fully vested.

SEC source: 0001209191-22-000647 · doc4.xml · nonDerivative · entry 5

TAHL CINDY · CIK 0001655472 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 169,006

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 8, 2021.

F5 · price: Represents the weighted average sale price of the shares sold ranging from $60.30 to $60.33 per share.

SEC source: 0001209191-22-000647 · doc4.xml · nonDerivative · entry 4

TAHL CINDY · CIK 0001655472 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 169,867

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 8, 2021.

F4 · price: Represents the weighted average sale price of the shares sold ranging from $59.30 to $60.29 per share.

SEC source: 0001209191-22-000647 · doc4.xml · nonDerivative · entry 3

TAHL CINDY · CIK 0001655472 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 197,679

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 8, 2021.

F3 · price: Represents the weighted average sale price of the shares sold ranging from $58.26 to $59.25 per share.

SEC source: 0001209191-22-000647 · doc4.xml · nonDerivative · entry 2

TAHL CINDY · CIK 0001655472 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 214,579

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 8, 2021.

F2 · price: Represents the weighted average sale price of the shares sold ranging from $57.26 to $58.18 to per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 2 through 5.

SEC source: 0001209191-22-000647 · doc4.xml · nonDerivative · entry 1

TAHL CINDY · CIK 0001655472 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 219,006

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 8, 2021.

SEC source: 0001209191-21-070768 · doc4.xml · derivative · entry 3

Dulac Edward J III · CIK 0001821530 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 128,238

Underlying: Common Stock · 14,437 shares

Expires 2030-08-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 28, 2021.

F2 · derivative.exercise_date: The option shall vest as to 25% of the underlying shares on August 17, 2021 and thereafter on a monthly basis for 36 additional months, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date.

SEC source: 0001209191-21-070768 · doc4.xml · nonDerivative · entry 2

Dulac Edward J III · CIK 0001821530 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,404

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 28, 2021.

SEC source: 0001209191-21-070768 · doc4.xml · nonDerivative · entry 1

Dulac Edward J III · CIK 0001821530 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 126,381

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 28, 2021.

SEC source: 0001209191-21-069415 · doc4.xml · derivative · entry 7

Valamehr Bahram · CIK 0001748177 · Chief R&D Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,156

Underlying: Common Stock · 25,000 shares

Expires 2027-01-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 9, 2020.

F7 · derivative.exercise_date: This option is fully vested.

SEC source: 0001209191-21-069415 · doc4.xml · nonDerivative · entry 6

Valamehr Bahram · CIK 0001748177 · Chief R&D Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 156,698

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 9, 2020.

F6 · price: Represents the weighted average sale price of the shares sold from $49.21 to $49.40 per share.

SEC source: 0001209191-21-069415 · doc4.xml · nonDerivative · entry 5

Valamehr Bahram · CIK 0001748177 · Chief R&D Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 158,298

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 9, 2020.

F5 · price: Represents the weighted average sale price of the shares sold from $48.21 to $49.20 per share.

SEC source: 0001209191-21-069415 · doc4.xml · nonDerivative · entry 4

Valamehr Bahram · CIK 0001748177 · Chief R&D Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 166,016

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 9, 2020.

F4 · price: Represents the weighted average sale price of the shares sold from $47.21 to $48.20 per share.

SEC source: 0001209191-21-069415 · doc4.xml · nonDerivative · entry 3

Valamehr Bahram · CIK 0001748177 · Chief R&D Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 172,580

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 9, 2020.

F3 · price: Represents the weighted average sale price of the shares sold from $46.20 to $47.17 per share.

SEC source: 0001209191-21-069415 · doc4.xml · nonDerivative · entry 2

Valamehr Bahram · CIK 0001748177 · Chief R&D Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 179,598

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 9, 2020.

F2 · price: Represents the weighted average sale price of the shares sold from $45.18 to $46.17 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of he Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 6.

SEC source: 0001209191-21-069415 · doc4.xml · nonDerivative · entry 1

Valamehr Bahram · CIK 0001748177 · Chief R&D Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 181,698

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 9, 2020.

SEC source: 0001209191-21-069313 · doc4.xml · derivative · entry 9

Chu Yu-Waye · CIK 0001854586 · Senior VP Clinical Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,000

Underlying: Common Stock · 7,500 shares

Expires 2029-04-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020.

F8 · derivative.exercise_date: The option shall vest as to 25% of the underlying shares on April 15, 2020 and thereafter on a monthly basis for 36 additional months, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date

SEC source: 0001209191-21-069313 · doc4.xml · nonDerivative · entry 8

Chu Yu-Waye · CIK 0001854586 · Senior VP Clinical Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,758

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020.

SEC source: 0001209191-21-069313 · doc4.xml · nonDerivative · entry 7

Chu Yu-Waye · CIK 0001854586 · Senior VP Clinical Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 126,763

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020.

F7 · price: Represents the weighted average sale price of the shares sold ranging from $54.33 to $54.98 per share.

SEC source: 0001209191-21-069313 · doc4.xml · nonDerivative · entry 6

Chu Yu-Waye · CIK 0001854586 · Senior VP Clinical Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 126,363

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020.

F6 · price: Represents the weighted average sale price of the shares sold ranging from $53.10 to $54.02 per share.

SEC source: 0001209191-21-069313 · doc4.xml · nonDerivative · entry 5

Chu Yu-Waye · CIK 0001854586 · Senior VP Clinical Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 127,394

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020.

F5 · price: Represents the weighted average sale price of the shares sold ranging from $52.09 to $52.87 per share.

SEC source: 0001209191-21-069313 · doc4.xml · nonDerivative · entry 4

Chu Yu-Waye · CIK 0001854586 · Senior VP Clinical Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 129,216

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020.

F4 · price: Represents the weighted average sale price of the shares sold ranging from $50.96 to $51.22 per share.

SEC source: 0001209191-21-069313 · doc4.xml · nonDerivative · entry 3

Chu Yu-Waye · CIK 0001854586 · Senior VP Clinical Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,261

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020.

F3 · price: Represents the weighted average sale price of the shares sold ranging from $49.96 to $50.89 per share.

SEC source: 0001209191-21-069313 · doc4.xml · nonDerivative · entry 2

Chu Yu-Waye · CIK 0001854586 · Senior VP Clinical Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 131,161

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020.

F2 · price: Represents the weighted average sale price of the shares sold ranging from $48.95 to $49.87 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 2 through 7.

SEC source: 0001209191-21-069313 · doc4.xml · nonDerivative · entry 1

Chu Yu-Waye · CIK 0001854586 · Senior VP Clinical Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 133,258

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020.

SEC source: 0001209191-21-066156 · doc4.xml · nonDerivative · entry 1

Chu Yu-Waye · CIK 0001854586 · Senior VP Clinical Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,758

F1 · kind: These shares were granted pursuant to a performance-based restricted stock unit award. The units will vest in three approximately equal installments conditioned upon the achievement, on or before December 31, 2026, of up to three specified late-stage clinical and regulatory milestones of the issuer, so long as the reporting person continues to serve as an employee of the issuer through each milestone achievement.

SEC source: 0001209191-21-066168 · doc4.xml · nonDerivative · entry 3

Wolchko J Scott · CIK 0001586893 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 480,268

F2 · kind: These shares were granted pursuant to a performance-based restricted stock unit award. The units will vest in three approximately equal installments conditioned upon the achievement, on or before December 31, 2026, of up to three specified late-stage clinical and regulatory milestones of the issuer, so long as the reporting person continues to serve as an employee of the issuer through each milestone achievement.

SEC source: 0001209191-21-066165 · doc4.xml · nonDerivative · entry 1

Valamehr Bahram · CIK 0001748177 · Chief R&D Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 156,698

F1 · kind: These shares were granted pursuant to a performance-based restricted stock unit award. The units will vest in three approximately equal installments conditioned upon the achievement, on or before December 31, 2026, of up to three specified late-stage clinical and regulatory milestones of the issuer, so long as the reporting person continues to serve as an employee of the issuer through each milestone achievement.

SEC source: 0001209191-21-066163 · doc4.xml · nonDerivative · entry 1

TAHL CINDY · CIK 0001655472 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 169,006

F1 · kind: These shares were granted pursuant to a performance-based restricted stock unit award. The units will vest in three approximately equal installments conditioned upon the achievement, on or before December 31, 2026, of up to three specified late-stage clinical and regulatory milestones of the issuer, so long as the reporting person continues to serve as an employee of the issuer through each milestone achievement.

SEC source: 0001209191-21-066162 · doc4.xml · nonDerivative · entry 1

Plavsic Mark · CIK 0001868719 · Chief Technical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,540

F1 · kind: These shares were granted pursuant to a performance-based restricted stock unit award. The units will vest in three approximately equal installments conditioned upon the achievement, on or before December 31, 2026, of up to three specified late-stage clinical and regulatory milestones of the issuer, so long as the reporting person continues to serve as an employee of the issuer through each milestone achievement.

SEC source: 0001209191-21-066159 · doc4.xml · nonDerivative · entry 1

Dulac Edward J III · CIK 0001821530 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,944

F1 · kind: These shares were granted pursuant to a performance-based restricted stock unit award. The units will vest in three approximately equal installments conditioned upon the achievement, on or before December 31, 2026, of up to three specified late-stage clinical and regulatory milestones of the issuer, so long as the reporting person continues to serve as an employee of the issuer through each milestone achievement.

SEC source: 0001209191-21-066168 · doc4.xml · derivative · entry 4

Wolchko J Scott · CIK 0001586893 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,446

Underlying: Common Stock · 20,000 shares

Expires 2026-01-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020.

F3 · derivative.exercise_date: This option is fully vested.

SEC source: 0001209191-21-066168 · doc4.xml · nonDerivative · entry 2

Wolchko J Scott · CIK 0001586893 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 393,793

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020.

SEC source: 0001209191-21-066168 · doc4.xml · nonDerivative · entry 1

Wolchko J Scott · CIK 0001586893 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 413,793

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020.

SEC source: 0001209191-21-061485 · doc4.xml · derivative · entry 11

Wolchko J Scott · CIK 0001586893 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,446

Underlying: Common Stock · 15,154 shares

Expires 2026-01-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020.

F4 · derivative.exercise_date: This option is fully vested.